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Two systematic reviews of literature have been conducted. One focused on the
efficacy, identifying health technology agencies reports, meta-analysis, systematic
reviews, and randomized controlled trials (RCTs). The safety systematic review
included the previous designs plus observational studies. In the latter review, stud-
ies in subsequent lines of treatment were considered. Searches were done in MED-
LINE, EMBASE, CRD, and the Cochrane Library until the 8th of June. The quality
assessment of the studies was done with the SIGN and CASPe tools. Two authors
independently selected the studies, assessed the quality, and performed the data
extraction, with disagreements resolved by a third reviewer until consensus was
obtained. RESULTS: In the efficacy systematic review, three RCTs were included.
The chemotherapy in one of these trials was FOLFIRI, in another trial FOLFOX-4,
and in the other one was oxaliplatin and fluoropyrimidine chemotherapy. In the
safety systematic review, five RCTs (3 studies in first-line, one study in second-line
and another with cetuximab in monotherapy in subsequent lines), and an obser-
vational study were considered. Cetuximab in combination with FOLFIRI improved
overall survival (OS), resection rate, progression free survival (PFS) and overall
tumour response rate (RR). Whereas, an increase in terms of OS was not observed
with cetuximab in combination with oxaliplatin based regimen, and different re-
sults were obtained in PFS. The only benefit observed with the later regimen was in
the RR. In terms of safety, cetuximab increased grade 3 or 4 skin toxicity.
CONCLUSIONS: The benefit of the addition of cetuximab to standard therapy for
previously untreated mCRC, KRAS wild-type patients differs depending on the
chemotherapy associated, with an improvement in all the outcomes when FOLFIRI
is used.
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OBJECTIVES: 5-hydroxytryptamine3 receptor antagonists (5-HT3 RAs) are used for
prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This study
compared the risk of severe CINV associated with hospitalization or emergency
room admission among patients with lymphoma initiated and maintained on
palonosetron versus the other 5-HT3 RAs (granisetron, ondansetron, and
dolasetron).METHODS:Adult patients diagnosed with lymphoma and treated with
cyclophosphamide were selected from PharMetrics claims data (2005-2009). Other
inclusion criteria were continuous patient enrollment for at least6 months before
the initial diagnosis and receipt of 5-HT3 RA for CINV prevention on the day of
cyclophosphamide treatment (index date). CINV was identified by ICD-9-CM claims
for nausea, vomiting, and/or dehydration. Risk of CINV during the follow-up period
of 6 months from index date was assessed using multiple regression models, con-
trolling for age, gender, Charlson Comorbidity Index (CCI), and total dose of
cyclophosphamide. RESULTS: A total of 2609 patients were studied. Palonosetron
patients (n979; 37.5%) were older than the other 5-HT3 RAs (62.1 13.6 vs. 59.0
14.1 years, p0.0001), with similar CCI and gender. During follow-up, palonosetron
patients received more cyclophosphamide dose in significantly fewer CT days
(586 mg; p0.0005 and -0.73 days, both p0.0001), and had fewer patients expe-
riencing unadjusted severe CINV (7.3% vs. 10.4%, p0.007) as compared to the other
5-HT3 RA patients. Multiple regressions found that palonosetron group (versus the
other 5-HT3 RA group) experienced fewer CINV claims (0.47 less; p0.0253), fewer
CINV days (48% less; p0.0006), and a 34% lower severe CINV risk (Odds Ratio0.66;
p0.006). CONCLUSIONS: Patients in palonosetron group received higher CT dose
within fewer CT days and experienced significantly lower risk for potentially costly
CINV events than patients on other 5-HT3-RA-based antiemetic prophylaxis. Fur-
ther studies on the clinical and economic impact of the choice of 5-HT3-RA for CINV
prophylaxis in patients with lymphoma are needed.
PCN5
REDUCED RISK OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN
PATIENTS WITH CANCER TREATED WITH HIGHLY EMETOGENIC
CHEMOTHERAPY AND ANTIEMETIC PROPHYLAXIS WITH PALONOSETRON
Schwartzberg L1, Jackson J2, Jain G2, Balu S3
1Accelerated Community Oncology Research Network, Memphis, TN, USA, 2Xcenda, LLC., Palm
Harbor, FL, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: Palonosetron, dolasetron, granisetron, and ondansetron [5-HT3 re-
ceptor antagonists (5-HT3-RAs)] are indicated to prevent chemotherapy-induced
nausea and vomiting (CINV). This study assessed the risk of uncontrolled CINV
following antiemetic prophylaxis with palonosetron  dexamethasone (group 1)
versus any of the other 5-HT3-RAs  dexamethasone (group 2) among single-day
HEC cycles in cancer diagnosed patients. METHODS: Single-day HEC cycles (a gap
of at least 5 days between 2 administrations) among patients with a cancer diag-
nosis and initiating antiemetic prophylaxis with group 1 versus group 2 between
June 1, 2006 to June 30, 2010 were identified from the IMS LifeLink claims database.
Uncontrolled CINV events were defined as nausea, vomiting, or dehydration ICD-
9-CM codes, hydration CPT codes, rescue medications, and/or use of antiemetic
therapy from days 2-5 post-HEC administration. Risk for an uncontrolled CINV
event was analyzed at cycle level using a logistic multivariate regression model
controlling for key variables. RESULTS: A total of 67,873 group 1 and 26,540 group 2
cycles (17,272 and 7,365 patients, respectively) were analyzed. Groups 1 and 2 were
similar in age [mean (sd): 55.0 (12.3) vs. 55.3 (12.6) years; p0.1502], Charlson co-
morbidity score [6.2 (3.2) vs. 6.2 (3.2); p0.7949], and female distribution (74.7% vs.
73.7%; p0.0893). Versus group 2, group 1 patients had a higher percent of breast
cancer (45.0% vs. 42.2%; p0.0001) and a lower percent of lymph/hematologic ma-
lignancies (11.6% vs. 13.4%; p0.0002). Group 1 cycles had a significantly lower
unadjusted risk of an uncontrolled CINV event (14.1% vs. 15.4%; p0.0001), while
the regression analysis predicted a 10% lower risk for group 1 cycles [Odds Ratio:
0.90 (95% CI: 0.86 – 0.93); p0.0001]. CONCLUSIONS: In this retrospective claims
data analysis, patients with cancer receiving single-day HEC cycles and group 1
prophylaxis for CINV had a lower risk for an uncontrolled CINV event versus group
2 prophylaxis.
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OBJECTIVES: Palonosetron, dolasetron, granisetron, and ondansetron [5-HT3 re-
ceptor antagonists (5-HT3-RAs)] are indicated to prevent chemotherapy-induced
nausea and vomiting (CINV). This study assessed the risk of uncontrolled CINV
following antiemetic prophylaxis with palonosetron  dexamethasone (group 1)
versus any of the other 5-HT3-RAs  dexamethasone (group 2) among single-day
HEC cycles in cancer diagnosed patients. METHODS: Single-day HEC cycles (a gap
of at least 5 days between 2 administrations) among patients with a cancer diag-
nosis and initiating antiemetic prophylaxis with group 1 versus group 2 between
June 1, 2006 to June 30, 2010 were identified from the IMS LifeLink claims database.
Uncontrolled CINV events were defined as nausea, vomiting, or dehydration ICD-
9-CM codes, hydration CPT codes, rescue medications, and/or use of antiemetic
therapy from days 2-5 post-HEC administration. Risk for an uncontrolled CINV
event was analyzed at cycle level using a logistic multivariate regression model
controlling for key variables. RESULTS: A total of 67,873 group 1 and 26,540 group 2
cycles (17,272 and 7,365 patients, respectively) were analyzed. Groups 1 and 2 were
similar in age [mean (sd): 55.0 (12.3) vs. 55.3 (12.6) years; p0.1502], Charlson co-
morbidity score [6.2 (3.2) vs. 6.2 (3.2); p0.7949], and female distribution (74.7% vs.
73.7%; p0.0893). Versus group 2, group 1 patients had a higher percent of breast
cancer (45.0% vs. 42.2%; p0.0001) and a lower percent of lymph/hematologic ma-
lignancies (11.6% vs. 13.4%; p0.0002). Group 1 cycles had a significantly lower
unadjusted risk of an uncontrolled CINV event (14.1% vs. 15.4%; p0.0001), while
the regression analysis predicted a 10% lower risk for group 1 cycles [Odds Ratio:
0.90 (95% CI: 0.86 – 0.93); p0.0001]. CONCLUSIONS: In this retrospective claims
data analysis, patients with cancer receiving single-day HEC cycles and group 1
prophylaxis for CINV had a lower risk for an uncontrolled CINV event versus group
2 prophylaxis.
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OBJECTIVES: The incidence of febrile neutropenia (FN) depends on the cancer type
and the chemotherapy regimen used. In Belgium, reimbursement of granulocyte-
colony stimulating factors (G-CSF) in primary prophylaxis against FN is limited to 4
indications. This study aimed to provide real-life information on the incidence and
impact of FN in chemotherapy-cancer combinations excluded from G-CSF primary
prophylaxis reimbursement. METHODS: Based on ICD-9 code and drug name all
chemotherapy-cancer combinations with at least one patient having an ICD-9 code
corresponding to neutropenia (288.0) and/or fever (780.6) and where G-CSF primary
prophylaxis was not reimbursed, were retrieved from the IMS Hospital Disease
database for the period 2005-2008. This database includes longitudinal (per calen-
dar year) information on diagnoses and drugs prescribed in about 34% of all Belgian
hospital beds. Incidence of FN (cases of FN with chemo-cancer combination di-
vided by total number of patients with this chemo-cancer combination), mortality
in patients with and without FN and impact of FN on subsequent chemotherapy
treatment decisions were assessed. RESULTS: Among the 25,544 patients at risk,
3,191 (13%) had at least one FN episode. Highest incidence rates were found in
combinations of cisplatin-containing regimens with head and neck (71/287, 25%),
stomach (24/110, 22%) and esophagus (36/202, 18%) cancers, lung cancers treated
with cisplatin-etoposide (52/292, 18%) or carboplatin-etoposide (102/659, 16%) reg-
imen and multiple myeloma treated with doxorubicin-vincristine regimen (26/152,
17%). Overall, 50% of first FN episodes occurred during cycle 1. Of the 3191 FN
patients 11% died, 24% switched chemotherapy regimen and 22% stopped treat-
ment during the cycle with FN. FN occurred subsequently in 27% of 1367 patients
continuing the same regimen. CONCLUSIONS: This study suggests clinically sig-
nificant FN-incidence is associated with chemotherapy regimens where G-CSF pri-
mary prophylaxis is not reimbursed in Belgium, which may lead to negative out-
comes in terms of mortality and treatment disruption.
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